Brazil's Anvisa approves Kineret for rheumatoid arthritis and rare autoinflammatory diseases

Brazil's National Health Surveillance Agency (Anvisa) granted registration to Kineret (anakinra) on 27 July. The interleukin‑1 blocking drug is now authorized for the treatment of rheumatoid arthritis in adults who do not respond adequately to methotrexate, as well as for several autoinflammatory conditions: cryopyrin‑associated periodic syndromes (CAPS), Familial Mediterranean Fever, and Still's disease. The approval covers patients of all ages, including children and infants from eight months old who weigh at least 10 kg.

Kineret will be available in Brazil as part of combination therapy for rheumatoid arthritis and as a monotherapy for the listed periodic‑fever syndromes and Still's disease, expanding therapeutic options for patients with persistent systemic inflammation and related functional impairment.